We are live on ! Find out more
NWBOW

Northwest Biotherapeutics, Inc.
NWBOW

Delisted

NWBOW was delisted on the 16th of December, 2016.

Back to rankings

2 hedge funds and large institutions have $1K invested in Northwest Biotherapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$432
2
WAM
Wolverine Asset Management
Illinois
+$286

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$1K +$432 +1,508 New
WAM
2
Wolverine Asset Management
Illinois
– +$286 +1,000 +200%

NWBOW Hedge Fund Activity: Q3 2016 in Review

2 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q3 2016, worth a combined $1K.

Buyers outnumbered sellers: 1 fund opened new NWBOW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $432.

  • 2 institutional investors held Northwest Biotherapeutics, Inc. (NWBOW) as of Q3 2016, up from 1 in Q2 2016.
  • Funds reported $1K of Northwest Biotherapeutics, Inc. stock for Q3 2016.
  • 1 fund opened new Northwest Biotherapeutics, Inc. positions in Q3 2016 and 0 closed out, a net change of +1 holder.
  • The largest Northwest Biotherapeutics, Inc. buyer in Q3 2016 was UBS Group, an estimated $432 added.

Based on aggregated 13F filings for Q3 2016.